ReviewAntimicrobial agents and chemotherapy2011
Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance.
Review in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 206 citations in OpenAlex.
- A Biological Approach to Antimicrobial Resistance in New and Old Bacterial Pathogens.Pathogens (Basel, Switzerland) · 2026Review
- Impaired Membrane Energetics Underlies Collateral Sensitivity to Amphenicols During Meropenem Resistance Evolution inMicroorganisms · 2026Article
- Unexpected enrichment of antibiotic resistance genes in recirculating aquaculture effluents of rainbow trout (Frontiers in microbiology · 2026Article
- Genomic characterization of Staphylococcus epidermidis Se252 isolated from the rhizosphere of a Brazilian endemic plant.BMC genomics · 2025Article
- Microbial interactions as the key to understanding and controlling environmental spread of antibiotic resistance genes.npj antimicrobials and resistance · 2025Article
- Evolution of Resistant Mutants inMicroorganisms · 2025Article
- The application of bacteriophage to veterinary and One-Health medicine-a road map.Frontiers in microbiology · 2025Review
- Review of the Structural Characteristics and Biological Activities ofMolecules (Basel, Switzerland) · 2024Review
- Sub-inhibitory antibiotic treatment selects for enhanced metabolic efficiency.Microbiology spectrum · 2024Article
- Interception of Epoxide ring to quorum sensing system in Enterococcus faecalis and Staphylococcus aureus.AMB Express · 2023Article
- What are the missing pieces needed to stop antibiotic resistance?Microbial biotechnology · 2023Review
- Article
- Prevalence and Phenotypic and Molecular Characterization of Carbapenemase-Producing Gram-Negative Bacteria in Gabon.The American journal of tropical medicine and hygiene · 2023Article
- New Variants of PseudomonasMicroorganisms · 2022Article
- Secondary Metabolites of Actinomycetales as Potent Quorum Sensing Inhibitors Targeting Gram-Positive Pathogens: In Vitro and In Silico Study.Metabolites · 2022Article
- DNA Breaks-Mediated Fitness Cost Reveals RNase HI as a New Target for Selectively Eliminating Antibiotic-Resistant Bacteria.Molecular biology and evolution · 2021Article
- Antibacterial fatty acids: An update of possible mechanisms of action and implications in the development of the next-generation of antibacterial agents.Progress in lipid research · 2021Review
- Metformin as a Potential Adjuvant Antimicrobial Agent Against Multidrug Resistant Bacteria.Clinical pharmacology : advances and applications · 2021Article
- Novel Molecular Markers Linked toAntibiotics (Basel, Switzerland) · 2021Article
- NSAIDs as a Drug Repurposing Strategy for Biofilm Control.Antibiotics (Basel, Switzerland) · 2020Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the explosive spread of antibiotic resistance determinants among pathogenic, commensal, and environmental bacteria has reached a global dimension. Classical measures trying to contain or slow locally the progress of antibiotic resistance in patients on the basis of better antibiotic prescribing policies have clearly become insufficient at the global level. Urgent measures are needed to directly confront the processes influencing antibiotic resistance pollution in the microbiosphere. Recent interdisciplinary research indicates that new eco-evo drugs and strategies, which take ecology and evolution into account, have a promising role in resistance prevention, decontamination, and the eventual restoration of antibiotic susceptibility. This minireview summarizes what is known and what should be further investigated to find drugs and strategies aiming to counteract the "four P's," penetration, promiscuity, plasticity, and persistence of rapidly spreading bacterial clones, mobile genetic elements, or resistance genes. The term "drug" is used in this eco-evo perspective as a tool to fight resistance that is able to prevent, cure, or decrease potential damage caused by antibiotic resistance, not necessarily only at the individual level (the patient) but also at the ecological and evolutionary levels. This view offers a wealth of research opportunities for science and technology and also represents a large adaptive challenge for regulatory agencies and public health officers. Eco-evo drugs and interventions constitute a new avenue for research that might influence not only antibiotic resistance but the maintenance of a healthy interaction between humans and microbial systems in a rapidly changing biosphere.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.